Hofseth BioCare ASA (HOFBF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 156.04 Million NOK | 2352.97% |
| 2022 | 6.94 Million NOK | -13.02% |
| 2021 | 7.98 Million NOK | 23.44% |
| 2020 | 6.46 Million NOK | 34.21% |
| 2019 | 4.81 Million NOK | -94.15% |
| 2018 | 82.36 Million NOK | 379.83% |
| 2017 | 17.16 Million NOK | -68.01% |
| 2016 | 53.65 Million NOK | -1.16% |
| 2015 | 54.28 Million NOK | -16.56% |
| 2014 | 65.06 Million NOK | -17.18% |
| 2013 | 78.56 Million NOK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.15 Million USD | 45.27% |
| 2024 Q1 | 2.29 Million USD | 32.69% |
| 2023 Q3 | 1.64 Million USD | -1.89% |
| 2023 FY | 170.35 Million USD | 2352.97% |
| 2023 Q1 | 1.65 Million USD | 2.13% |
| 2023 Q2 | 1.67 Million USD | 1.13% |
| 2023 Q4 | 1.84 Million USD | 12.21% |
| 2022 Q3 | 1.47 Million NOK | -11.84% |
| 2022 Q2 | 1.67 Million NOK | -27.36% |
| 2022 FY | 6.94 Million NOK | -13.02% |
| 2022 Q1 | 2.3 Million NOK | 75.1% |
| 2022 Q4 | 1.61 Million NOK | 9.61% |
| 2021 Q4 | 1.31 Million NOK | -39.89% |
| 2021 Q3 | 2.19 Million NOK | 16.2% |
| 2021 FY | 7.98 Million NOK | 23.44% |
| 2021 Q1 | 1.8 Million NOK | -94.91% |
| 2021 Q2 | 1.88 Million NOK | 4.31% |
| 2020 Q4 | 35.51 Million NOK | 9.03% |
| 2020 Q1 | 28.26 Million NOK | 6.47% |
| 2020 FY | 6.46 Million NOK | 34.21% |
| 2020 Q2 | 25.46 Million NOK | -9.92% |
| 2020 Q3 | 32.57 Million NOK | 27.92% |
| 2019 Q4 | 26.55 Million NOK | 45.51% |
| 2019 FY | 4.81 Million NOK | -94.15% |
| 2019 Q3 | 18.24 Million NOK | -11.8% |
| 2019 Q2 | 20.68 Million NOK | -10.32% |
| 2019 Q1 | 23.07 Million NOK | -3.57% |
| 2018 Q3 | 22.8 Million NOK | 8.32% |
| 2018 Q2 | 21.05 Million NOK | -8.71% |
| 2018 Q1 | 23.06 Million NOK | 19.99% |
| 2018 FY | 82.36 Million NOK | 379.83% |
| 2018 Q4 | 23.92 Million NOK | 4.9% |
| 2017 FY | 17.16 Million NOK | -68.01% |
| 2017 Q3 | 18.29 Million NOK | -3.55% |
| 2017 Q1 | 19.04 Million NOK | -12.29% |
| 2017 Q2 | 18.96 Million NOK | -0.38% |
| 2017 Q4 | 19.22 Million NOK | 5.08% |
| 2016 Q4 | 21.7 Million NOK | 77.5% |
| 2016 Q2 | 12.29 Million NOK | -31.73% |
| 2016 Q1 | 18.01 Million NOK | -53.53% |
| 2016 FY | 53.65 Million NOK | -1.16% |
| 2016 Q3 | 12.22 Million NOK | -0.56% |
| 2015 Q4 | 38.76 Million NOK | 138.79% |
| 2015 Q2 | 15.41 Million NOK | 10.77% |
| 2015 Q1 | 13.91 Million NOK | -27.39% |
| 2015 FY | 54.28 Million NOK | -16.56% |
| 2015 Q3 | 16.23 Million NOK | 5.3% |
| 2014 Q1 | 18.02 Million NOK | -29.74% |
| 2014 Q4 | 19.16 Million NOK | 9.8% |
| 2014 Q3 | 17.45 Million NOK | 34.65% |
| 2014 Q2 | 12.96 Million NOK | -28.06% |
| 2014 FY | 65.06 Million NOK | -17.18% |
| 2013 Q4 | 25.64 Million NOK | 18.3% |
| 2013 Q1 | 20.4 Million NOK | 4.57% |
| 2013 Q2 | 18.83 Million NOK | -7.69% |
| 2013 FY | 78.56 Million NOK | 0.0% |
| 2013 Q3 | 21.68 Million NOK | 15.11% |
| 2012 Q3 | 11.18 Million NOK | -23.76% |
| 2012 Q2 | 14.67 Million NOK | -2.99% |
| 2012 Q4 | 19.51 Million NOK | 74.43% |
| 2012 Q1 | 15.12 Million NOK | 89.96% |
| 2011 Q3 | 5.9 Million NOK | 13.48% |
| 2011 Q2 | 5.2 Million NOK | -12.99% |
| 2011 Q1 | 5.97 Million NOK | -23.91% |
| 2011 Q4 | 7.96 Million NOK | 34.93% |
| 2010 Q4 | 7.85 Million NOK | 433.86% |
| 2010 Q3 | 1.47 Million NOK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | -428.011% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2994.836% |
| CSL Limited | 3.44 Billion USD | 95.476% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -318.844% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -16796.731% |
| BioStem Technologies, Inc. | 22.97 Million USD | -579.192% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1335.934% |
| Qrons Inc. | 643.67 Thousand USD | -24142.438% |
| Nascent Biotech, Inc. | 2.22 Million USD | -6897.824% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -171.663% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -2222.755% |
| Skye Bioscience, Inc. | 13.54 Million USD | -1051.817% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -37457.374% |
| Rebus Holdings, Inc. | 664 Thousand USD | -23400.452% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -874.645% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -11584.842% |
| Genscript Biotech Corporation | 825.34 Million USD | 81.094% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -39955.6% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -79.804% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -3072.952% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -59520.748% |
| SQZ Biotechnologies Company | 85.61 Million USD | -82.253% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -5250.838% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -10289.713% |
| Mesoblast Limited | 5.9 Million USD | -2543.9% |
| Marizyme, Inc. | 19.23 Million USD | -711.041% |
| Genus plc | 147.7 Million USD | -5.649% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1677.41% |
| Pharming Group N.V. | 225.49 Million USD | 30.799% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -7516.665% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -11531.589% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1771.244% |
| ContraFect Corporation | 56.88 Million USD | -174.294% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -3439.456% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -10452.344% |
| IMV Inc. | 37.7 Million USD | -313.806% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -5492.224% |
| MultiCell Technologies, Inc. | 567.42 USD | -27500340.591% |
| ONE Bio Corp. | 6.44 Million USD | -2321.564% |
| Accustem Sciences Inc. | 3.74 Million USD | -4065.124% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -81.561% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -29233.486% |
| Q BioMed Inc. | 3.43 Million USD | -4440.585% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -531.37% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5838.789% |
| Biomind Labs Inc. | 994.18 Thousand USD | -15595.617% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -57.095% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -8767.702% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -8269.744% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 624272.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -8403.265% |
| GB Sciences, Inc. | 1.42 Million USD | -10885.006% |
| Alpha Cognition Inc. | 9.7 Million USD | -1507.762% |
| HST Global, Inc. | 140.9 Thousand USD | -110641.837% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -13771.599% |
| Halberd Corporation | 74.84 Thousand USD | -208396.566% |
| Enzolytics Inc. | 2.17 Million USD | -7059.555% |
| Agentix Corp. | 1.37 Million USD | -11275.42% |
| Resverlogix Corp. | 12.71 Million USD | -1127.525% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -4174.323% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 89.825% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -14846.648% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -6388.452% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -9780.173% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -4482.789% |
| AVAX Technologies, Inc. | 7.31 Million USD | -2034.574% |
| Zenith Capital Corp. | 8.94 Million USD | -1644.862% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -895617.812% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -6255.31% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -90882.397% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -8023.406% |
| Kadimastem Ltd | 2.41 Million USD | -6374.512% |
| Helix BioMedix, Inc. | 1.97 Million USD | -7812.795% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -85881.211% |
| LadRx Corporation | 3.81 Million USD | -3993.692% |
| Cell Source, Inc. | 4.32 Million USD | -3507.642% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -16796.731% |
| NovAccess Global Inc. | 2.46 Million USD | -6225.826% |
| Affymax, Inc. | 39.38 Million USD | -296.189% |
| Itoco Inc. | 919.14 Thousand USD | -16877.01% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3581.637% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -13844.861% |
| Mobile Lads Corp. | 554.54 Thousand USD | -28038.874% |
| CytoDyn Inc. | 18.05 Million USD | -764.121% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -619880.929% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -70803.498% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -10890.554% |
| SYBLEU INC | 160.87 Thousand USD | -96895.823% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -8491.162% |
| International Stem Cell Corporation | 5.27 Million USD | -2860.406% |
| Bioxytran, Inc. | 3.82 Million USD | -3984.738% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -296323.008% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -766959.922% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -330.274% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -9544.19% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -21106.249% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4915.847% |
| Neutra Corp. | 243.82 Thousand USD | -63898.999% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -793.871% |
| PureTech Health plc | 144.59 Million USD | -7.916% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -661.561% |
| IXICO plc | 4.7 Million USD | -3215.126% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1673.821% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -32.523% |
| CSL Limited | 3.89 Billion USD | 95.992% |
| Cellectis S.A. | 97.32 Million USD | -60.34% |